Tag
This review synthesizes evidence comparing brain atrophy patterns in MS, MOGAD, and AQP4+ NMOSD, highlighting MOGAD’s atrophy association with inflammatory activity and lesion dynamics, emphasizing distinct pathogenic mechanisms and c
This article evaluates spinal MRI features in AQP4-IgG+ NMOSD myelitis, highlighting the diagnostic specificity of bright spotty lesions, the double-contoured LETM sign, and sagittal ring enhancement for differentiating NMOSD from other mye
A retrospective study reveals that 24% of patients meeting the latest MS criteria following optic neuritis actually have MOGAD or NMOSD, emphasizing the need for antibody testing to prevent misdiagnosis.
A multicenter study reveals that nearly one-quarter of patients meeting the newest multiple sclerosis criteria for optic neuritis actually have MOGAD or NMOSD, emphasizing the critical role of antibody screening and detailed orbital MRI in
This review analyzes how age at onset influences NMOSD, revealing that while relapse risk remains constant across age groups, older onset significantly accelerates disability progression, necessitating early high-efficacy therapy.
This article reviews the long-term safety and efficacy of satralizumab in neuromyelitis optica spectrum disorder based on the SAkuraMoon extension trial.
